DexCom DXCM will be releasing its next round of earnings Tuesday. For all of the relevant information, here is your guide for today's Q4 earnings announcement.
Earnings and Revenue
Based on DexCom management projections, analysts predict EPS of 3 cents per share on revenue of $215.74 million.
In the same quarter last year, DexCom reported an earnings loss of 9 cents per share on revenue of $171.2 million. The analyst consensus estimate would represent a 133.33 percent increase in the company's earnings. Sales would be up 26.02 percent on a year-over-year basis.
DexCom's reported EPS has stacked up against analyst estimates in the past like this:
| Quarter | Q3 2017 | Q2 2017 | Q1 2017 | Q4 2016 |
| EPS Estimate | -0.16 | -0.21 | -0.5 | -0.1 |
| EPS Actual | -0.04 | -0.16 | -0.49 | -0.09 |
Stock Performance
Over the last 52-week period, shares are down -27.71 percent. Given that these returns are generally negative, long-term shareholders are probably down going into this earnings release.
Analyst estimates have adjusted higher for EPS and revenues over the past 90 days. The average rating by analysts on DexCom stock is a Neutral. The strength of this rating has maintained conviction over the past 90 days.
Conference Call
DexCom's Q4 conference call is scheduled to begin at 4:30 p.m. ET and can be accessed here.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
